Company Filing History:
Years Active: 2012-2013
Title: Kenji Matsuo: Innovator in Tyrosine Kinase Inhibitory Compounds
Introduction
Kenji Matsuo is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit tyrosine kinases. His work has the potential to impact therapeutic strategies for various diseases.
Latest Patents
Matsuo holds 2 patents related to quinazoline derivatives that exhibit tyrosine kinase inhibitory activity. These compounds are designed to inhibit both the EGF receptor tyrosine kinase and HER2 tyrosine kinase. The general formula of these compounds includes various substituents that enhance their pharmacological properties, making them valuable in the pharmaceutical industry.
Career Highlights
Kenji Matsuo is associated with Shionogi & Company Limited, a well-respected pharmaceutical company. His research focuses on innovative solutions to combat diseases through targeted therapies. His expertise in medicinal chemistry has positioned him as a key figure in his field.
Collaborations
Matsuo has collaborated with notable colleagues, including Masaharu Kume and Naoki Omori. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic compounds.
Conclusion
Kenji Matsuo's contributions to the field of medicinal chemistry, particularly through his innovative patents, highlight his role as a leading inventor. His work continues to pave the way for advancements in targeted therapies.